Mirum Pharmaceuticals, Inc. - common stock (MIRM): Price and Financial Metrics

Mirum Pharmaceuticals, Inc. - common stock (MIRM): $17.46

-0.14 (-0.80%)

POWR Rating

Component Grades














  • MIRM scores best on the Sentiment dimension, with a Sentiment rank ahead of 93.02% of US stocks.
  • The strongest trend for MIRM is in Growth, which has been heading up over the past 163 days.
  • MIRM ranks lowest in Momentum; there it ranks in the 9th percentile.

MIRM Stock Summary

  • Mirum Pharmaceuticals Inc's stock had its IPO on July 18, 2019, making it an older stock than just 5.89% of US equities in our set.
  • With a price/sales ratio of 34.2, Mirum Pharmaceuticals Inc has a higher such ratio than 94.76% of stocks in our set.
  • With a year-over-year growth in debt of 3,691.28%, Mirum Pharmaceuticals Inc's debt growth rate surpasses 99.46% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Mirum Pharmaceuticals Inc are CDAK, MRUS, KYMR, ADAP, and ARCT.
  • Visit MIRM's SEC page to see the company's official filings. To visit the company's web site, go to mirumpharma.com.

MIRM Valuation Summary

  • MIRM's price/sales ratio is 45.1; this is 297.36% higher than that of the median Healthcare stock.
  • MIRM's price/sales ratio has moved NA NA over the prior 26 months.
  • Over the past 26 months, MIRM's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for MIRM.

Stock Date P/S P/B P/E EV/EBIT
MIRM 2021-08-31 45.1 5.2 -3.2 -3.6
MIRM 2021-08-30 44.4 5.1 -3.2 -3.6
MIRM 2021-08-27 45.1 5.2 -3.2 -3.6
MIRM 2021-08-26 43.1 5.0 -3.1 -3.5
MIRM 2021-08-25 42.1 4.8 -3.0 -3.4
MIRM 2021-08-24 41.3 4.7 -3.0 -3.4

MIRM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MIRM has a Quality Grade of C, ranking ahead of 49.16% of graded US stocks.
  • MIRM's asset turnover comes in at 0.052 -- ranking 319th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows MIRM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.052 1 -0.949
2021-03-31 0.000 NA -1.229
2020-12-31 0.000 NA -1.146
2020-09-30 0.000 NA -0.934
2020-06-30 0.000 NA -0.781
2020-03-31 0.000 NA -0.694

MIRM Price Target

For more insight on analysts targets of MIRM, see our MIRM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $51.33 Average Broker Recommendation 1.29 (Strong Buy)

MIRM Stock Price Chart Interactive Chart >

Price chart for MIRM

MIRM Price/Volume Stats

Current price $17.46 52-week high $22.14
Prev. close $17.60 52-week low $12.82
Day low $16.99 Volume 37,140
Day high $17.73 Avg. volume 127,765
50-day MA $15.48 Dividend yield N/A
200-day MA $16.51 Market Cap 534.94M

Mirum Pharmaceuticals, Inc. - common stock (MIRM) Company Bio

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.

MIRM Latest News Stream

Event/Time News Detail
Loading, please wait...

MIRM Latest Social Stream

Loading social stream, please wait...

View Full MIRM Social Stream

Latest MIRM News From Around the Web

Below are the latest news stories about Mirum Pharmaceuticals Inc that investors may wish to consider to help them evaluate MIRM as an investment opportunity.

Analysts’ Top Healthcare Picks: Mirum Pharmaceuticals (MIRM)

There's a lot to be optimistic about in the Healthcare sector as 1 analysts just weighed in on and Mirum Pharmaceuticals (MIRM – Research Report) with bullish sentiments. Mirum Pharmaceuticals (MIRM) In a report issued on January 11, Mani Foroohar from Leerink Partners maintained a Buy rating on Mirum Pharmaceuticals. The company's shares closed last Friday at $18.74. According to TipRanks.

Christine Brown on TipRanks | January 17, 2022

Mesirow Financial Investment Management, Inc. ...

Investment company Mesirow Financial Investment Management, Inc. (Current Portfolio) buys Green Brick Partners Inc, Cadre Holdings Inc, Identiv Inc, Atlanticus Holdings Corp, Andersons Inc, sells TriState Capital Holdings Inc, The Joint Corp, Mirum Pharmaceuticals Inc, Genasys Inc, CareDx Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Mesirow Financial Investment Management, Inc..

Yahoo | January 14, 2022

H.C. Wainwright Keeps a Buy Rating on Mirum Pharmaceuticals (MIRM)

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Mirum Pharmaceuticals (MIRM – Research Report), with a price target of $64.00. The company's shares closed last Tuesday at $15.92. According to TipRanks.com, Arce is a 4-star analyst with an average return of 14.4% and a 38.4% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Paratek Pharmaceuticals. Mirum Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $57.67.

Brian Anderson on TipRanks | January 12, 2022

Mirum Pharmaceuticals (MIRM) Investor Presentation - Slideshow

The following slide deck was published by Mirum Pharmaceuticals, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | January 11, 2022

Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones

FOSTER CITY, Calif., January 11, 2022--Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones

Yahoo | January 11, 2022

Read More 'MIRM' Stories Here

MIRM Price Returns

1-mo N/A
3-mo 11.42%
6-mo 23.22%
1-year -10.78%
3-year N/A
5-year N/A
YTD 9.47%
2021 -8.65%
2020 -28.79%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7478 seconds.